Background. Calcineurin inhibitor (CNI)-based therapy is associated with adverse cardiovascular effects. We examined the effects of late CNI or mycophenolate mofetil (MMF) withdrawal on echocardiographic parameters. Methods. This study was conducted as a substudy of a randomized trial in stable renal transplant recipients on a triple CNI-based regimen with prednisone and MMF that evaluated late concentration-controlled withdrawal of the CNI or MMF on renal function. A total of 108 patients (age, 52.3±11.5 years, 67% male, at a median of 2.0 years after transplantation (interquartile range 1.3-3.3 years), estimated glomerular filtration rate, 57±16 mL/min/1.73 m 2 , 66% on cyclosporine and 34% on tacrolimus) entered the car-
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Late calcineurin inhibitor withdrawal prevents progressive left ventricular diastolic dysfunction in renal transplant recipients Jacqueline S. Mourer 
INTRODUCTION
The introduction of newer immunosuppressants, and the calcineurin inhibitors (CNIs) in particular, has significantly reduced acute rejection rates, but the recent epidemiological data continue to indicate that long-term graft survival has not improved accordingly 1 . Chronic allograft dysfunction, currently defined by interstitial fibrosis and tubular atrophy, remains the dominant cause of late graft loss and CNI-induced, acute and/or chronic, nephrotoxicity is considered an important contributor to the progression of chronic allograft dysfunction 2 . Moreover, CNI-based therapy has unfavourable cardiovascular side effects such as hypertension, dyslipidemia and new-onset diabetes 3 . To date, cardiovascular disease (CVD) remains the leading cause of morbidity and mortality after renal transplantation. Previous studies have shown that patients with end-stage renal disease (ESRD) already have a high cardiovascular risk burden at the initiation of dialysis with left ventricular hypertrophy (LVH) as the most commonly observed cardiac abnormality [4] [5] . LVH is an important determinant of sudden cardiac death and heart failure both in the general population and in dialysis patients 4, 6 . Additionally, left atrial (LA) dilatation has also been shown to be an independent predictor of all-cause mortality in ESRD patients, beyond that of left ventricular (LV) mass and systolic function [7] [8] . Favourable structural cardiac changes, such as LV mass regression and improvement of LV function, that may alter the long-term cardiovascular risk, have been described after renal transplantation [9] [10] [11] [12] .
Currently, there are conflicting data regarding the effects of calcineurin on the myocardium. A recent study in cardiac transplant recipients reported that replacement of the CNI with sirolimus resulted in LV mass regression, with an improvement in diastolic function 13 . In experimental animals, however, calcineurin activation appears to be a key player in mediating the development of LVH, and calcineurin inhibition could prevent LVH without affecting LV systolic function 12, [14] [15] . Moreover, genetic inhibition of calcineurin has failed to result in LVH development in a mouse model but, instead, resulted in diastolic dysfunction 16 .
In a recently reported randomized trial in stable renal transplant recipients, we assessed the impact of late concentration-controlled CNI or mycophenolate mofetil (MMF) withdrawal on renal function after 3 years 17 . CNI elimination resulted in better renal function, whereas the risk of acute rejection was low in both withdrawal groups. We report the results of a cardiovascular substudy that evaluated the impact of CNI or MMF withdrawal on echocardiographic parameters 2 years after randomization. were not available to complete the 2-year follow-up visit. In the MMF-based group: 1 patient died, 1 returned to dialysis, 1 developed a posttransplantation proliferative disorder, 1 did not show for the 2-year visit and 2 withdrew informed consent owing to the perceived intensity of outpatient visits. In the CNI-based group, 3 patients died, 1 developed a Merkel cell tumor and 1 withdrew consent. The recipient-, donor-and transplant procedure-related factors of the 108 patients, who completed the 2-year follow-up visit, are summarized in Table 1 . There were no significant differences between the randomized groups with respect to the type of transplant, time posttransplantation, immunological or cardiovascular risk profile. At baseline, there were also no differences in systolic blood pressure (SBP), diastolic blood pressure (DBP) or proportions of patients with the target blood pressure (BP) of lower than 130/85 mm Hg. 
RESULTS

Patients
Clinical follow-up
In the first 6 months after randomization, 2 patients in the MMF-based (3.8%) and 1 patient in the CNI-based group (1.8%) experienced an acute rejection episode (P=0.49). Two (3.8%) patients in the MMF-based and 3 (5.5%) in the CNI-based group had a cardiac event (P=1.00). In the MMF-based group, 1 patient had atrial fibrillation and 1 had endocarditis; in the CNI-based group, 1 patient had supraventricular tachycardia and 2 had myocardial infarction. During follow-up, the immunosuppressive regimen was changed The clinical characteristics at 2 years are summarized in Table 2 . At 2 years, patients in the CNI-based group had a higher mean arterial pressure (P=0.002), SBP (P=0.06) and DBP (P=0.001). More patients in the MMF-based group achieved the predefined target BP of lower than 130/85 mm Hg (41.5% vs.12.7%, P=0.001). In addition, compared with that at baseline, a higher proportion of patients reached the target BP in the MMF-based group (baseline, 18.9%; 2 years, 41.5%; P=0.01). In the CNI-based group, less patients achieved the target BP (baseline, 21.8%; 2 years, 12.7%; P=0.36) and there was a trend to use more antihypertensive drugs (≥2 drugs; P=0.06). Overall, the type of antihypertensive drugs used did not differ between the groups. Despite the increased use of angiotensin converting enzyme inhibitors (ACE-i) or angiotensin receptor blockers in both groups, the estimated glomerular filtration rate (eGFR) remained better in the MMF-based group (59±17 vs. 54±17 mL/min/1.73 m 2 , P=0.11, Table 2 ). Six weeks after CNI withdrawal, the Δ-eGFR was 4.5±1.0 mL/min/1.73 m 2 in the MMF-based group versus 0.8±1.0 mL/min/1.73 m 2 in CNI-based patients (P=0.012). The Δ-eGFR between week 6 after randomization and year 2 was not significantly different between the groups (P=0.42). There was no difference in the degree of proteinuria, as assessed by repeated urine albumin/creatinine ratios. A significant decrease in lipid levels was observed (P<0.001) in both groups, but there were no significant differences between the groups. There was also no significant difference in the proportions of patients with diabetes mellitus or in the glycated hemoglobin (HbA1c) levels.
Echocardiography
There were no significant differences in echocardiographic variables between the groups at baseline ( For LV diastolic function for the entire group, mitral deceleration time was significantly increased compared with that at baseline (from 196.4±50.4 to 207.8±51.7 ms, P=0.013). Similarly, the LA volume index increased from 23.2±6.4 to 25.2±7.1 mL/m 2 (P<0.001) at 2 years. Table 3 summarizes the changes in echocardiographic parameters using linear mixed models and after adjustment by randomization arm, MMF-based versus CNI-based therapy. Compared with baseline, there were no differences between the groups in changes in LVEDV, LVESV indices and LVEF after 2 years (Table 3 ). In particular, LV mass index did not show any significant change over time in the overall population or in 1 of the randomized groups ( Table 3) .
The assessment of LV diastolic function, however, demonstrated a significantly larger and more rapid prolongation of E-wave deceleration time (from 195.5±56.8 to 217.8±57.5 ms, P<0.05) in the CNI-based group, whereas the E-wave deceleration time remained unchanged (from 197.5±43.0 to 197.0±42.6 ms) in the MMF-based group (Fig. 1A) . The association between changes in E-wave deceleration time and randomization arm remained significant after correcting for changes in eGFR, SBP and DBP, and body mass index over time (P=0.025; Fig. 1A ). Using linear mixed models, the changes in E-wave deceleration time were not associated with changes in eGFR (P=0.17), SBP (P=0.53), DBP (P=0.55) or body mass index (P=0.21).
Mitral annular e' velocity demonstrated a significant improvement at 2 years in the MMF-based group (from 6.0±1.8 to 6.6±2.0 cm/s, P<0.05), but remained unchanged in the CNI-based group (from 6.2±2.1 to 6.1±2.1 cm/s, P=0.53, Table 3 ).
LA volume index was subsequently employed to assess the effects of chronic LV diastolic dysfunction. There was a significantly larger and more rapid increase in LA volume index (from 24.1±6.7 to 27.0±7.0 mL/m 2 , P<0.001, Fig. 1B ) in the CNI-based group at followup. In contrast, no change in LA volume index was observed in the MMF-based group Table 3 ). The LA volume index increased by 12%
in patients who continued the CNI at 2 years. Conversely, the LA volume index increased only marginally by 4% in patients who had their CNI withdrawn (mean change, 2.9±5.0 vs. 0.9±4.4 mL/m 2 , P=0.03). The larger and more rapid increase in LA volume index observed in the CNI-based group remained significant after correcting for changes in eGFR, SBP and DBP, and body mass index (P<0.001, Fig. 1B ). Using linear mixed models, the changes in LA volume index were significantly associated with treatment group (P=0.03) and changes in SBP (P=0.005) and DBP (P=0.005). However, changes in eGFR (P=0.19) and body mass index (P=0.70) over time did not significantly influence the observed changes in LA volume index. The interobserver and intraobserver reproducibility of the echocardiographic measurements are outlined in Table 4 . Overall, intraobserver and interobserver reproducibility were good for the different echocardiographic measurements, with very small biases and narrow limits of agreement. 
DISCUSSION
This is the first study to indicate that late CNI withdrawal from a triple-drug regimen in stable renal transplant recipients could prevent progressive development of LV diastolic dysfunction, as determined by mitral deceleration time and mitral annular e' velocity. Furthermore, LA volume index, an indicator of the chronicity and severity of LV diastolic dysfunction 18 , continued to increase in patients who had MMF withdrawn and remained on CNI therapy during the 2-year follow-up period. Additionally, this randomized study demonstrated that MMF-based maintenance therapy facilitated better BP control. This study was conducted as a cardiovascular substudy of a prospective randomized trial, which demonstrated that late concentration-controlled CNI withdrawal resulted in better renal function compared with MMF withdrawal, with a low risk of acute rejection after 3 years 17 . Although most randomized studies have shown an improvement in renal function, (early) CNI withdrawal has been associated with an increased risk of acute rejection [19] [20] [21] [22] . The risk of rejection in these studies was, however, higher in the patients with lower mycophenolic acid (MPA) exposure 19, [22] [23] . The results of the main study indicated that area under the concentration-over-time curve (AUC) monitoring of the remaining drug prevents underdosing while reducing the risk of acute rejection after late CNI withdrawal. This study highlighted that, despite employing strict predefined BP targets and treatment protocol, BP was still insufficiently controlled in a significant proportion of patients at 2 years. This finding is in agreement with previous cohort studies [24] [25] , which documented that 46% of renal recipients may have SBP of 140 mm Hg or higher at 1 year posttransplantation 24 . This is particularly accentuated in patients who continued on CNI-based therapy, because they had significantly higher BP compared with patients with MMF-based maintenance therapy. CNIs have multiple mechanisms by which they may promote arterial hypertension [26] [27] . First, CNIs promote afferent arteriolar vasoconstriction via the sympathetic nervous system and upregulation of the renin-angiotensinaldosterone system 28 . Furthermore, they reduce the secretion of vasodilator cytokines while mediating an increase in vasoconstrictor cytokines. Accordingly, the prevalence of posttransplant hypertension was reported to be significantly increased (50-60%) after the introduction of CNIs in the 1980s 29 .
Poor BP control has been associated with inferior allograft function and long-term outcomes in renal transplant recipients, and conscious efforts should be made to optimize BP control in this population 25, 30 . The present study showed that CNI withdrawal facilitated better BP control. Arterial hypertension is a well-known risk factor for LVH and heart failure in patients with renal failure including transplant recipients 31 . In the present study, however, no significant change in LV mass was observed at 2 years between the 2 groups, despite the significantly higher BP observed in the patients who remained on CNI-based therapy. A few explanations may support this observation. First, on the basis of the following criteria-LV mass index greater than 134 g/m 2 (men) and greater than 110 g/m 2 (women)
-most of our patients did not have LVH at the time of randomization [32] [33] . In fact, only 22.2% (8/36) of our female and 11.1% (8/72) of our male patients had LVH criteria at baseline. Therefore, it is not surprising that no significant interval change in LV mass was observed in our population, in whom LVH was only present in a minority before randomization. Second, there may have been a role for the strict clinical treatment protocol we introduced to titrate antihypertensive medications according to predefined BP targets. Furthermore, the use of ACE-i or angiotensin receptor blockers was high in the present study, with most of the patients (70.4%) using 2 or more antihypertensive drugs already before randomization. Because the renin-angiotensin-aldosterone system is activated in CNI-treated patients 34 , antagonizing it with an ACE-i or angiotensin receptor blocker may suppress the renin-angiotensin-aldosterone system-mediated cell growth and perhaps LVH development. Finally, there are conflicting data regarding the effect of calcineurin on cardiac hypertrophy [13] [14] [15] [16] 35 . In mice models, the activation of calcineurin has been shown to play a role in mediating the development of LVH. Its inhibition, either by CNI administration or the genetic inhibition of calcineurin, could prevent LVH [14] [15] [16] , although other investigators were not able to show similar observation 35 . Therefore, the present study also does not support the hypothesis that CNI withdrawal could result in LV mass regression. Nonetheless, the present study documented that CNI withdrawal from a triple-drug regimen in stable renal transplant recipients, prevented progressive development of LV diastolic dysfunction. Furthermore, significant increases in LA volumes at 2 years were observed in patients who continued their CNI, also after adjusting for changes in eGFR, BP and body mass index. These changes were significantly influenced by changes in SBP and DBP. In contrast, the patients allocated to the MMF-based group did not show changes in LA volume index. This group of patients reached the target BP (<130/85 mm Hg) in a significantly higher proportion than the patients in the CNI-continuation group. This seems to suggest that CNI withdrawal may stabilize LV diastolic dysfunction in patients with chronic renal disease, probably by also influencing BP control.
LV diastolic dysfunction develops early in most cardiac diseases and may be responsible for up to one third of patients with heart failure in the general population despite preserved LV systolic function 36 . In ESRD patients, at least 50-60% have LV diastolic dysfunction 37 . Impaired LV diastolic function and elevation in LV filling pressures are associated with high mortality in ESRD patients 38 . In addition, chronically elevated LV filling pressures will result in LA enlargement in the absence of significant valvular or primary myocardial diseases in patients with sinus rhythm 18 . In this regard, LA enlarge-ment has been shown to be an independent predictor of all-cause mortality in ESRD patients, beyond that of LV mass and systolic function [7] [8] .
Nevertheless, whether the favorable diastolic parameters observed in this study are reflective of the consequence of the indirect effects of better renal function or better BP control or the direct effect of CNI withdrawal, or all of these, remains to be ascertained. So far, CNI-based therapy has been associated with LVH development and myocardial fibrosis and contributes to diastolic abnormalities of the cardiac allograft in heart transplant patients 39 . Moreover, a recent study has indicated that LV diastolic dysfunction progressed after renal transplantation, despite LVH regression and improvement in LV systolic function, and suggested that cyclosporine treatment may be the cause of worsening LV diastolic function 11 . Thus, it seems conceivable that by arresting LV diastolic dysfunction with CNI withdrawal (as indicated by the present study), a more favorable cardiovascular risk profile can be expected in renal transplant recipients. In summary, the present study provides evidence that late CNI withdrawal with MMF prevents progressive development of LV diastolic dysfunction, an important parameter of cardiovascular morbidity and mortality in renal transplant recipients [7] [8] 38 . In addition, the MMF-based regimen allows better BP control compared with CNI-based maintenance therapy. Several limitations should be acknowledged. First, the present study is a single-center study in a selected group of renal transplant recipients, with stable renal allograft function at a median of 2 years after transplantation and with a relatively low immunological risk profile. Therefore, the results may not be directly extrapolated to other populations. Second, this study was not designed to discriminate between the adverse effects of CNIs on BP and renal function or the myocardium itself. Finally, the assessment of myocardial fibrosis content with current imaging techniques would have strengthened the results of the present study. However, this goal was beyond the scope of the present study.
MATERIALS AND METHODS
Study design and patients
The main study was a prospective, open-label, randomized-controlled single-center trial that enrolled a total of 177 renal transplant recipients and evaluated renal function after 3 years 17 . Stable patients on CNI-based maintenance therapy with MMF and steroids, at least 6 months after transplantation with a stable eGFR of 30 mL/min/1.73 m 2 or greater, were randomized to CNI or MMF withdrawal. All patients were randomized with stratification for previous acute rejection and prior cardiovascular events (including myocardial infarction or percutaneous coronary interventions). Patients were dosed using a population-based pharmacokinetic model, limited sampling and Bayesian estima-tion [40] [41] . The predefined targets for the AUC 0-12 were for mycophenolic acid AUC of 75 μg·h/mL (range, 60-90 μg·hr/mL) for the MMF-based therapy group, and cyclosporine AUC of 3250 ng·hr/mL (range, 3000-3500 ng·hr/mL) and tacrolimus AUC of 120 ng·hr/ mL (range, 100-140 ng·h/mL) for the CNI-based therapy group. MMF or CNI doses were reduced with 50% every 2 weeks and completely withdrawn after 4 weeks. Concomitant with complete withdrawal, the prednisone dose was temporarily increased to 20 mg (1 week), 15 mg (1 week) and then back to baseline. Patients on tacrolimus were maintained on 5 mg per day prednisolone; all the other patients received 7.5 to 10 mg per day. A total of 119 patients from the main study participated in the current cardiovascular substudy (NCT00169910). This study was designed to investigate the progression of surrogate CVD markers including echocardiographic parameters at baseline and 2 years after randomization. Patients with documented moderate or severe valvular disease on echocardiography were excluded from the study.
The study was performed in conformity to the Declaration of Helsinki, Good Clinical Practice guidelines. Informed consent was obtained from all patients. The study was approved by the Leiden University Medical Center Ethics Committee.
Clinical follow-up
All patients were followed in a dedicated outpatient clinic and treated according to predefined targets of care: hypertension 42 -SBP lower than 130 mm Hg and DBP lower than 85 mm Hg or, in case of proteinuria, SBP lower than 125 mm Hg and DBP lower than 75 mm Hg. The mean BP was recorded by averaging 3 repeated measurements in sitting position after a 5-minute rest, using a digital BP monitor. The target low density lipoprotein (LDL) cholesterol was less than 2.6 mmol/L. BP, weight, concomitant medication, eGFR, proteinuria, cholesterol and HbA1c levels were recorded at baseline, every 3 months during the first year and at 2 years.
Echocardiographic assessment
All patients in the cardiovascular substudy underwent transthoracic echocardiography before randomization and at 2 years. All patients were in sinus rhythm at the time of randomization. Images were performed using a commercially available system (Vingmed Vivid-7, General Electric Vingmed, Horten, Norway) equipped with a 3.5-MHz transducer. Standard LV dimensions were obtained from the parasternal long-axis view at end-diastole and end-systole. Subsequently, LV mass was calculated according to the Devereux method and indexed to body surface area (BSA) [43] [44] . In addition, standard apical 2-and 4-chamber views were obtained. LVEDV and LVESV were measured and indexed to BSA, and LVEF was calculated using the biplane Simpson method 43 . Similarly, LA volumes were measured using the biplane Simpson method and indexed to BSA 43 . The assessment of LV diastolic function was performed by pulsed-wave Doppler examination of the mitral inflow from the apical 4-chamber view. The ratio between the transmitral early (E-wave) and late (A-wave) diastolic filling velocities and deceleration time of the E-wave were obtained 45 . Tissue Doppler imaging of the mitral annulus was also performed and the early diastolic mitral annular velocities (e') were recorded 45 . The ratio of transmitral E-wave to e' (E/e' ratio), a marker of LV filling pressures, was obtained 46 . Finally, LV global function was evaluated using the myocardial performance index (a measure of both systolic and diastolic performance). This was obtained by measuring the Doppler time intervals between the mitral inflow and LV outflow tract velocity curves 47 .
Outcome measures
The outcome of the present cardiovascular substudy was the change in echocardiographic parameters after 2 years of randomization, which served as surrogate markers of CVD. The primary outcome of the principal study was the change in Modification of Diet in Renal Disease (MDRD) clearance from baseline after randomization to CNI or MMF withdrawal. The secondary outcomes included incidence of acute rejection, proteinuria, patient death, kidney graft loss, BP and lipid profile.
Statistical analysis
The analyses were performed on an intention-to-treat basis. A sample size of 63 patients per group was calculated to have an 80% power to detect an increase in eGFR of 10 mL/ min, assuming a standard deviation of 20 mL/min and α(2-z)=0.05. The power of the actual sample size was 88% in the principal study. Continuous variables are presented as mean±standard deviation and categorical variables are presented as frequencies and percentages. For comparison between interval variables the Student t (parametric) or Mann-Whitney (nonparametric) test was used. Categorical variables were compared by a chi-square test, Fisher exact test or Kendall τ-b test. The changes in echocardiographic parameters over time were analyzed with linear mixed models adjusted initially for treatment group. The effect of changes in eGFR, SBP and DBP, and body mass index over time were subsequently introduced in the model as covariates to test whether these parameters had also an independent influence on the echocardiographic parameters. A linear mixed model was used to analyze the longitudinal data of renal function. The model assumed that the eGFR level of each patient at baseline might change after withdrawal and then follow a linear trend. The null hypothesis was tested that there were no differences in the change after withdrawal and the slopes of the subsequent trend of eGFR over time between the 2 groups. The interobserver and intraobserver reproducibility of the echocardiographic measurements were evaluated with the Bland-Altman analysis in 30 randomly selected echocardiography examinations. Two independent observers performed the measurements, blinded to test the interobserver variability. The same observer performed the measurements at two different time points. The mean bias and the 2 standard deviations are provided. A P<0.05 was considered to be statistically significant. All analyses were performed using SPSS software (version 16.0; SPSS Inc, Chicago, IL).
